Advertisement

Topics

GSK invests $139m to increase Benlysta (belimumab) production capacity

19:00 EDT 3 May 2017 | Pharmaceutical Technology

GSK is investing $139m in its biopharmaceutical manufacturing site located in Rockville, Maryland, to expand the production of Benlysta (belimumab).

Original Article: GSK invests $139m to increase Benlysta (belimumab) production capacity

NEXT ARTICLE

More From BioPortfolio on "GSK invests $139m to increase Benlysta (belimumab) production capacity"

Quick Search
Advertisement
 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...